Androgenetic alopecia affects an estimated 80 million people in the United States alone, yet the last FDA-approved prescription treatment for it arrived nearly 30 years ago. That gap is now drawing renewed clinical attention, and a new investigational drug is emerging as one of the more closely watched candidates in the space.
VDPHL01, an extended-release oral minoxidil tablet developed by Veradermics, is currently in Phase 3 development for pattern hair loss in both men and women. Unlike immediate-release oral minoxidil, which produces peak concentrations that can carry cardiovascular risk, the extended-release formulation is designed to deliver a steadier, more sustained absorption of the active ingredient, maintaining levels above the minimum threshold required for hair growth for longer periods.
What Is Being Studied
Two poster presentations at the 2026 Music City SCALE Symposium in Nashville are putting early comparative data into the clinical conversation. The first is a blinded retrospective assessment in which nine independent dermatologists evaluated VDPHL01’s perceived efficacy at two and four months against published six-month data on both oral and topical immediate-release minoxidil.
The second uses Global HairMap, an AI-based analysis platform, to compare androgenetic alopecia outcomes between VDPHL01 at four months and immediate-release oral minoxidil at six months.
Why the Comparison Matters
The standard of care for pattern hair loss has largely remained unchanged for decades. Topical minoxidil carries adherence challenges, and oral immediate-release minoxidil, while effective, is associated with side effects linked to its peak absorption profile. An extended-release formulation that could deliver comparable or superior outcomes with a more favourable safety profile would address a longstanding clinical gap.
The Broader Picture
Pattern hair loss is the largest aesthetics market globally, projected to reach approximately 30 billion dollars by 2028. With no new approved prescription options in a generation, the pipeline pressure is considerable.
VDPHL01 remains investigational and is not yet approved, but the data being presented this week adds to a growing body of evidence that the treatment landscape for alopecia may finally be shifting
